For the six-month period ended September 2023, the company earned 48.5% of its total revenue from rooms and 26.5% from the food and beverages segment. The sale of wine and liquor along with food and beverages together accounted for 42.11% of the total income during the period.
Biocon shares rise 2% on 10-year Pertuzumab supply deal for breast cancer therapy in Brazil
Biocon shares rose after the company secured a 10-year Pertuzumab supply contract in Brazil. The consortium with Bahiafarma and Bionovis received full allocation under the